Companies are continuing to rush out IPOs before the mid-August lull. This past week saw 11 IPOs and one SPAC raise $3.4 billion. Nine went public with market caps over $1 billion, including Chinese e-commerce app Pinduoduo, the...read more
Aquestive Therapeutics, a drug manufacturer developing oral film formulations of CNS disease therapies, raised $68 million by offering 4.5 million shares at $15, within the range of $14 to $16. Insiders intended to purchase $20 million of the IPO (30% of the...read more
Aquestive Therapeutics, a drug manufacturer developing oral film formulations of CNS disease therapies, announced terms for its IPO on Monday. The Warren, NJ-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to...read more
There are no deals set to price in the upcoming week. Following the most active quarter for IPOs in three years (check out Renaissance Capital's 2Q18 US IPO Review for additional insights), the market...read more
US IPO Weekly Recap: Growth stocks surge in 11 IPO week
Companies are continuing to rush out IPOs before the mid-August lull. This past week saw 11 IPOs and one SPAC raise $3.4 billion. Nine went public with market caps over $1 billion, including Chinese e-commerce app Pinduoduo, the...read more
Aquestive Therapeutics prices upsized IPO at $15 midpoint
Aquestive Therapeutics, a drug manufacturer developing oral film formulations of CNS disease therapies, raised $68 million by offering 4.5 million shares at $15, within the range of $14 to $16. Insiders intended to purchase $20 million of the IPO (30% of the...read more
Oral drug delivery biotech Aquestive Therapeutics sets terms for $60 million IPO
Aquestive Therapeutics, a drug manufacturer developing oral film formulations of CNS disease therapies, announced terms for its IPO on Monday. The Warren, NJ-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to...read more
US IPO Week Ahead: No IPOs expected, but over 10 deals could launch
There are no deals set to price in the upcoming week. Following the most active quarter for IPOs in three years (check out Renaissance Capital's 2Q18 US IPO Review for additional insights), the market...read more